Literature DB >> 11441217

Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB.

Z Zhang1, I Nagata, H Kikuchi, J H Xue, N Sakai, H Sakai, H Yanamoto.   

Abstract

BACKGROUND AND
PURPOSE: Plasma serine protease cascade, including the complement system and thrombin, is activated in the subarachnoid space during the acute phase after subarachnoid hemorrhage (SAH). To examine the effect of protease cascade-based inflammation and subsequent vascular repair in the development of cerebral vasospasm, we examined the effect of 2 synthetic serine protease inhibitors-FUT-175, an inhibitor of thrombin and the complement system, and argatroban, a selective inhibitor of thrombin-on the development of cerebral vasospasm in a rabbit SAH model.
METHODS: One hundred Japanese White male rabbits were used in the study. The SAH was simulated by a single injection of autologous arterial blood into the cisterna magna. To evaluate the development of cerebral vasospasm, the caliber of the basilar artery was measured on x-ray film before and at 2 days after SAH. Nine groups of rabbits (n=6 each) were treated with continuous intravenous injection of FUT-175 (2.5, 5, 10, or 20 mg/d), argatroban (1.25, 2.5, or 5 mg/d), or the same amount of saline (vehicle) for 48 hours, starting 40 minutes after SAH. Two days after SAH, the expression of homodimer of platelet-derived growth factor-BB (PDGF-BB) in the basilar artery was examined with immunohistochemical techniques. In 20 normal rabbits, 5 microg of recombinant PDGF-BB or vehicle was injected into the cisterna magna, and the basilar arteries were examined on angiograms for 48 hours.
RESULTS: Significant differences were observed in the caliber of the basilar arteries between the vehicle group and the groups with the 3 larger doses of FUT-175 (vehicle, 52+/-5.0%; 5 mg, 79+/-5.7%; 10 mg, 80+/-2.5%; 20 mg, 80+/-3.7%) and between the vehicle group and the groups with the 2 larger doses of argatroban (vehicle, 52+/-6.4%; 2.5 mg, 81+/-9.0%; 5 mg, 85+/-4.1%) (P<0.05). In the histological examination, administration of effective doses of FUT-175 or argatroban suppressed the expression of PDGF-BB in the endothelial and medial smooth muscle cell layers. Exogenous PDGF-BB caused delayed and prolonged vasoconstriction on normal basilar arteries.
CONCLUSIONS: Activation of the serine protease cascade and/or thrombin after SAH was demonstrated to play an essential role in the development of cerebral vasospasm. The expression of PDGF-BB-like protein in the arterial walls correlated with the development of cerebral vasospasm. Elevated PDGF-BB level in the subarachnoid space was found to induce delayed and chronic vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441217     DOI: 10.1161/01.str.32.7.1665

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid haemorrhage.

Authors:  Katsuharu Kameda; Yuichiro Kikkawa; Mayumi Hirano; Satoshi Matsuo; Tomio Sasaki; Katsuya Hirano
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 2.  Brain ischemia in patients with intracranial hemorrhage: pathophysiological reasoning for aggressive diagnostic management.

Authors:  Daniel Naranjo; Michal Arkuszewski; Wojciech Rudzinski; Elias R Melhem; Jaroslaw Krejza
Journal:  Neuroradiol J       Date:  2013-12-18

Review 3.  The single and double blood injection rabbit subarachnoid hemorrhage model.

Authors:  Yuichiro Kikkawa; Ryota Kurogi; Tomio Sasaki
Journal:  Transl Stroke Res       Date:  2014-11-08       Impact factor: 6.829

4.  Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy.

Authors:  Cheryl A Miller; Frederick W Lombard; Ching-Tang Wu; Cory J Hubbard; Lydia Silbajoris; Cecil O Borel; Laura E Niklason
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 5.  Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.

Authors:  J Marc Simard; David Schreibman; E Francois Aldrich; Bernadette Stallmeyer; Brian Le; Robert F James; Narlin Beaty
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

6.  Up-regulation of proteinase-activated receptor 1 and increased contractile responses to thrombin after subarachnoid haemorrhage.

Authors:  Y Maeda; K Hirano; Y Kai; M Hirano; S O Suzuki; T Sasaki; H Kanaide
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

7.  Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study.

Authors:  Luo Fei; Filimon Golwa
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  The rise of soluble platelet-derived growth factor receptor β in CSF early after subarachnoid hemorrhage correlates with cerebral vasospasm.

Authors:  Jing-Peng Liu; Zhen-Nan Ye; Sheng-Yin Lv; Zong Zhuang; Xiang-Sheng Zhang; Xin Zhang; Wei Wu; Lei Mao; Yue Lu; Ling-Yun Wu; Jie-Mei Fan; Wen-Ju Tian; Chun-Hua Hang
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

Review 9.  Inflammatory Pathways Following Subarachnoid Hemorrhage.

Authors:  Kevin Min Wei Khey; Alec Huard; Sherif Hanafy Mahmoud
Journal:  Cell Mol Neurobiol       Date:  2019-12-05       Impact factor: 5.046

Review 10.  The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.

Authors:  Fenghui Ye; Hugh J L Garton; Ya Hua; Richard F Keep; Guohua Xi
Journal:  Transl Stroke Res       Date:  2020-09-29       Impact factor: 6.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.